A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapvir for HIV Pre-Exposure Prophylaxis (PrEP) in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary people 18 Years of Age or Older who Have Sex with Male Partners and are at Risk of HIV Infection.